Status:
RECRUITING
A Prospective Evaluation of Microwave Ablation (MWA) in the Treatment of Relapsed Graves' Disease
Lead Sponsor:
The University of Hong Kong
Conditions:
Graves Disease
Minimally Invasive Treatment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Graves' disease is the most common cause of hyperthyroidism, with conventional treatment options being anti-thyroid drugs (ATD), radioiodine (RAI) and surgery. For ATD, it has been the first-line trea...
Eligibility Criteria
Inclusion
- (a) age older than 18 years,
- (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more
- (c) absence of vocal cord immobility
Exclusion
- (a) patients who prefer or are indicated for surgery,
- (b) presence of head and/or neck disease preventing hyperextension of the neck,
- (c) history of thyroid cancer or other malignant tumours in the neck region,
- (d) history of neck irradiation,
- (e) severe Graves' ophthalmopathy,
- (f) large compressive goitre,
- (g) pregnancy or lactation, and
- (h) any contraindication to intravenous sedation.
Key Trial Info
Start Date :
July 4 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06506149
Start Date
July 4 2023
End Date
June 30 2026
Last Update
July 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Mary Hospital
Hong Kong, Hong Kong, 00000